Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advance in the Treatment of Pediatric Leukemia
| Advance in the Treatment of Pediatric Leukemia |
| Autore | Handgretinger Rupert |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (300 p.) |
| Soggetto topico |
Research & information: general
Chemistry |
| Soggetto non controllato |
acute lymphoblastic leukemia
pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody-drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910576878903321 |
Handgretinger Rupert
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmacogenomics and Personalized Medicine
| Pharmacogenomics and Personalized Medicine |
| Autore | Cecchin Erika |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (208 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
CYP2C9
VKORC1 warfarin warfarin initiation phase of therapy INR pharmacogenetics study pharmacogenomics pharmacogenetics genotype phenotype alleles precision medicine pharmacotranscriptomics high-throughput analysis childhood acute lymphoblastic leukemia clopidogrel acenocoumarol CDSS implementation azathioprine inflammatory bowel disease glutathione-S transferase pharmacokinetics nucleoside analogs microRNAs gene expression drug resistance AML cisplatin nephrotoxicity kidney injury genetic polymorphisms pre-emptive panel breast cancer subtype miRNA pathway crosstalk network precision drugs ovarian cancer platinum resistance focal copy number alterations whole exome sequencing personalized medicine human genetics pharmacology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557287703321 |
|
Cecchin Erika
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||